menu

Harnessing the Power of the Immune System to Manage Higher-Risk MDS

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Harnessing the Power of the Immune System to Manage Higher-Risk MDS

6 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
  • Overview

    Myelodysplastic syndrome (MDS) is a group of myeloid malignancies characterized by ineffective hematopoiesis, inflammation, and immune dysregulation in the setting of multiple genomic disruptions. Disease burdens associated with MDS encompass complications of the disease itself as well as those associated with transformation to acute myeloid leukemia (AML). Patients with high-risk MDS (HR-MDS) face even greater challenges, particularly when treated in community-based settings. This risk stems from the presence of greater numbers of cytogenetic abnormalities, which are unstable and associated with increased transformation to AML. Patients with HR-MDS and AML may not be candidates for allogeneic stem hematopoietic cell transplantation due to age or comorbidities. Hypomethylating agents (HMAs) remain as the standard of care for HR-MDS; however, responses to HMA do not exceed 50% and are short-lived. The efficacy of HMAs in some patients with MDS and their long-standing role in therapy have led to the development of novel treatment approaches that make use of HMA combination therapies with immune-based therapies, such as those that target the TIM-3 pathway.

    This educational activity will focus on assessing MDS risk and its relation to treatment choices, the rationale and mechanism of action for novel immune-based therapies and integrating emerging combination therapies into clinical practice.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies.  An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Andrew M. Brunner, MD reported a financial interest/relationship or affiliation in the form ofConsultant: Acceleron Pharma; Agios Pharmaceuticals, Inc; Bristol-Myers Squibb Co; Celgene Corp; Gilead; Keros Therapeutics; Novartis Pharmaceuticals Corp; Taiho Pharmaceutical Co, Ltd; and Takeda Oncology.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman,  PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is for community-based hematologists/oncologists and the interprofessional care team, such as pathologists/lab professionals, oncology nurses, nurse practitioners, pharmacists, and physician assistants who actively manage MDS.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Implement biomarker testing and prognostic scoring systems to define higher-risk MDS and guide treatment
    2. Discuss the evolving role of the immune system in MDS, including the various pathways involved in dysregulation such as the TIM-3 pathway
    3. Review efficacy results of immuno-myeloid therapy targeting TIM-3 in combination with HMAs as treatment for higher risk MDS
    4. Develop management plans to address adverse events related to novel and emerging therapies for MDS
  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until August 31st, 2023. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hours of continuing pharmacy education JA4008106-0000-22-031-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

  • Activity Credit(s) and Certificate(s)

    Method of Participation and Request for Credit
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
  • Overview

    Myelodysplastic syndrome (MDS) is a group of myeloid malignancies characterized by ineffective hematopoiesis, inflammation, and immune dysregulation in the setting of multiple genomic disruptions. Disease burdens associated with MDS encompass complications of the disease itself as well as those associated with transformation to acute myeloid leukemia (AML). Patients with high-risk MDS (HR-MDS) face even greater challenges, particularly when treated in community-based settings. This risk stems from the presence of greater numbers of cytogenetic abnormalities, which are unstable and associated with increased transformation to AML. Patients with HR-MDS and AML may not be candidates for allogeneic stem hematopoietic cell transplantation due to age or comorbidities. Hypomethylating agents (HMAs) remain as the standard of care for HR-MDS; however, responses to HMA do not exceed 50% and are short-lived. The efficacy of HMAs in some patients with MDS and their long-standing role in therapy have led to the development of novel treatment approaches that make use of HMA combination therapies with immune-based therapies, such as those that target the TIM-3 pathway.

    This educational activity will focus on assessing MDS risk and its relation to treatment choices, the rationale and mechanism of action for novel immune-based therapies and integrating emerging combination therapies into clinical practice.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies.  An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Andrew M. Brunner, MD reported a financial interest/relationship or affiliation in the form ofConsultant: Acceleron Pharma; Agios Pharmaceuticals, Inc; Bristol-Myers Squibb Co; Celgene Corp; Gilead; Keros Therapeutics; Novartis Pharmaceuticals Corp; Taiho Pharmaceutical Co, Ltd; and Takeda Oncology.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman,  PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is for community-based hematologists/oncologists and the interprofessional care team, such as pathologists/lab professionals, oncology nurses, nurse practitioners, pharmacists, and physician assistants who actively manage MDS.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Implement biomarker testing and prognostic scoring systems to define higher-risk MDS and guide treatment
    2. Discuss the evolving role of the immune system in MDS, including the various pathways involved in dysregulation such as the TIM-3 pathway
    3. Review efficacy results of immuno-myeloid therapy targeting TIM-3 in combination with HMAs as treatment for higher risk MDS
    4. Develop management plans to address adverse events related to novel and emerging therapies for MDS
  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until August 31st, 2023. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hours of continuing pharmacy education JA4008106-0000-22-031-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

  • Activity Credit(s) and Certificate(s)

    Method of Participation and Request for Credit
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule6 Dec 2022